NCT01373047View on ClinicalTrials.gov

CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Liver Metastases
Interventions
BIOLOGICAL

anti-CEA 2nd generation designer T cells

Three infusions of gene-modified T cells over the course of 6 weeks into the hepatic artery via a percutaneous approach.

Trial Locations (1)

02908

Roger Williams Medical Center, Providence

All Listed Sponsors
lead

Roger Williams Medical Center

OTHER

NCT01373047 - CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells | Biotech Hunter | Biotech Hunter